#MDLinkUp Twitter Chat Summary: Flu Vaccine

Since our first live #MDLinkUp Twitter Chat went so well we decided to hold a second session on flu vaccines at @MDLinx on September 22, 2016. With the flu season quickly approaching, many patients have similar questions for their physicians. We wanted to address some of them by going straight to the medical community. For those who aren’t aware, a Twitter Chat is a live, public Twitter conversation centered on one unique topic and a related hashtag. This hashtag allows users to follow the discussion and participate in the conversation. Using the #MDLinkUp hashtag we facilitated a conversation with our followers to tackle some basic questions about […]

In Case You Missed It: Early vs Delayed Use of Antiretroviral Therapy to Reduce Transmission of HIV-1 in Serodiscordant Couples

A recent study published in the New England Journal of Medicine reported that in 2014 there were more than 2 million new HIV-1 infections worldwide, most of which occurred via sexual transmission. Effective HIV-1 prevention strategies are required to reduce the risk of viral transmission from infected persons to their sexual partners. Other studies involving serodiscordant couples have suggested that antiretroviral therapy (ART) in those with HIV-1 infection reduces the risk of sexual transmission. The HIV Prevention Trials Network (HPTN) 052 trial, led by Myron S. Cohen, MD, was designed to determine the efficacy of antiretroviral therapy (ART) on preventing genetically-linked […]

#MDLinkUp Twitter Chat Summary: The Zika Virus

Recently, @MDLinx kicked off our inaugural #MDLinkUp Twitter Chat. For those who aren’t aware, a Twitter Chat is a live, public Twitter conversation centered on one unique topic and a related hashtag. This hashtag allows users to follow the discussion and participate in the conversation. Our first chat was focused on the Zika Virus, a topic that has been trending recently in the medical community and beyond. Using the #MDLinkUp hashtag we facilitated a conversation with our followers to tackle some basic questions about Zika, taking into account the latest research and prevention methodologies. Take a look at some of […]

In Case You Missed It: Daratumumab demonstrates significantly longer progression-free survival in multiple myeloma

Recently, results of a phase 3 trial performed by Antonio Palumbo, MD and other CASTOR investigators was published in the New England Journal of Medicine (N Engl J Med. 2016; 375:754-766) demonstrating the efficacy of daratumumab (16 mg/kg), an anti-CD38 monoclonal antibody, with bortezomib (1.3 mg/m2) plus dexamethasone (20 mg) in treatment of patients with relapses or relapsed and refractory multiple myeloma (n=498). Specifically, the progression-free survival (60.7% vs 26.9%), overall response (82.9% vs 63.2%), very good partial response or better (59.2% vs 29.1%), and complete response (19.2% vs 9.0%) was superior in the daratumumab with bortezomib plus dexamethasone group than […]